Search research articles
Contact Us
Filters
Showing results (311-320 of 347) with videos related to
Page
of 35
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 27, 2024
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)
Yuankai Shi, Jianhua Chen, Runxiang Yang, et al.
Experimental Hematology & Oncology
|
June 26, 2026
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study
Shengyu Zhou, Changgong Zhang, Guowen Wang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
Shun Lu, Jie Wang, Ying Cheng, et al.
The Lancet. Respiratory Medicine
|
December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
Lin Wang, Xuezhi Hao, Yanrong Hao, et al.
Theranostics
|
June 3, 2020
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
Qiaoyun Tan, Dan Wang, Jianliang Yang, et al.
Ebiomedicine
|
January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study
Lin Yang, Wen Zhang, Nanfeng Fan, et al.
BMC Cancer
|
January 24, 2024
Long-term outcomes with HLX01 (HanliKang<sup>®</sup>), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
Yan Qin, Yongping Song, Dong Wang, et al.
Signal Transduction and Targeted Therapy
|
January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
Yuankai Shi, Jian Fang, Xuezhi Hao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
Jianchun Duan, JiaChen Xu, Zhijie Wang, et al.
The Lancet. Oncology
|
April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.
Page
of 35
Search research articles
Search
Showing results (311-320 of 347) with videos related to
Sort By:
Page
of 35
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 27, 2024
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)
Yuankai Shi, Jianhua Chen, Runxiang Yang, et al.
Experimental Hematology & Oncology
|
June 26, 2026
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study
Shengyu Zhou, Changgong Zhang, Guowen Wang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
Shun Lu, Jie Wang, Ying Cheng, et al.
The Lancet. Respiratory Medicine
|
December 7, 2025
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
Lin Wang, Xuezhi Hao, Yanrong Hao, et al.
Theranostics
|
June 3, 2020
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients
Qiaoyun Tan, Dan Wang, Jianliang Yang, et al.
Ebiomedicine
|
January 13, 2024
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study
Lin Yang, Wen Zhang, Nanfeng Fan, et al.
BMC Cancer
|
January 24, 2024
Long-term outcomes with HLX01 (HanliKang<sup>®</sup>), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
Yan Qin, Yongping Song, Dong Wang, et al.
Signal Transduction and Targeted Therapy
|
January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
Yuankai Shi, Jian Fang, Xuezhi Hao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
Jianchun Duan, JiaChen Xu, Zhijie Wang, et al.
The Lancet. Oncology
|
April 17, 2016
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park, Eng-Huat Tan, Ken O'Byrne, et al.
Page
of 35